Pre-Eclampsia Clinical Trial
Official title:
Acid-base Disturbances and Ultrasound Markers as Biological Predictors of Maternal and Fetal Outcomes in Severe Late Onset Preeclampsia
Preeclampsia remains a leading cause of maternal morbidity and mortality, in both the
developed and developing world. It is a complex, multisystem disease which, in its severe
form, affects the cardiovascular, renal, hepatic, neurological and haematological systems.
The University of Cape Town-associated medical institutions alone were responsible for the
treatment of 800 women in 2014, who were classified as having preeclampsia with severe
features. Given the complexity of the disease, anesthetic management for Caesarean section
in these patients remains very challenging.
Recent studies have begun to demonstrate novel markers of preeclampsia severity, including
point-of-care ultrasound (POC-US) and acid-base (AB) abnormalities. For example, pilot
studies have demonstrated that approximately 25% of women diagnosed with severe preeclampsia
show signs of increased intracranial pressure and elevated lung water as evaluated by point
of care ultrasound. These findings could serve as noninvasive markers of disease severity,
and thus may be used to predict maternal and fetal outcome in preeclamptic women. Point of
care ultrasound is playing an increasing role in perioperative diagnosis, and newer, less
expensive devices are continuously being developed, and will in all likelihood play an
important role in South Africa in the near future.
In a recent trial performed at the University of Cape Town, a comprehensive acid-base
analysis in severe preeclamptic women demonstrated significant abnormalities in independent
acid-base determinants. In addition, strong indications were found that changes in acid-base
status in preeclampsia are more pronounced earlier in pregnancy and are associated with
urgent deliveries. As in other clinical arenas in critically ill patients, acid-base
abnormalities are associated with increased lung water, increased intracranial pressure, and
outcome, and we hypothesize that similar associations might be found in severe preeclamptic
women. Therefore, one aim of this study is to evaluate the association of venous acid base
abnormalities (an inexpensive and readily available test) observed in late onset severe
preeclampsia and organ manifestations identified with ultrasound, a well-validated and
robust tool for identifying these manifestations. Investigators will further examine the
association between ultrasound findings and/or venous acid-base abnormalities with urgent
delivery. It is intended to do a subsequent comparison between early- and late onset
preeclampsia, when a suitable tertiary site has been identified.
I. Introduction / Specific Aims Preeclampsia is a major cause of maternal mortality (15-20 %
in developed countries) and acute and long-term morbidity for the mother and newborn. It is
a multi-system disorder characterised by abnormal vascular response to placentation,
associated with increased systemic vascular resistance, enhanced platelet aggregation,
activation of the coagulation system, and endothelial dysfunction. Preeclampsia is defined
by a number of signs and symptoms, but is characterized by multi-organ changes that
encompass the central nervous system (CNS), lungs, liver, kidneys, systemic vasculature,
coagulation, and the heart .
Derived from other clinical arenas of intensive care medicine, new potential markers of
disease severity in women diagnosed with preeclampsia have recently been identified. Using
noninvasive point-of-care (POC) ultrasound, pulmonary interstitial edema and raised
intracranial pressure were identified in 25% and 20% respectively of women showing features
of severe preeclampsia. In addition, echocardiographic and laboratory studies in women
diagnosed with preeclampsia indicate an incidence of diastolic dysfunction and increased
left ventricular end-diastolic pressure (LVEDP) in up to 30%. These findings could have a
significant impact on maternal outcome and the detailed methodology of anesthesia care for
the parturient with severe preeclampsia (PreE), including the mode of anesthesia,
positioning of the patient, fluid management, and hemodynamic goals.
In a recent investigation performing a comprehensive physicochemical acid/base analysis in
pre-eclamptic women (AB-PreE-Trial), the presence of simultaneous hypoalbuminaemic alkalosis
and hyperchloraemic acidosis was identified. In addition, investigators found indications
that hypoalbuminaemic alkalosis is more marked in early versus late onset disease and is
associated with mode of delivery. In other critical care arenas it has been shown that
reduced albumin and acid-base abnormalities are associated with pulmonary interstitial
edema, elevated intracranial pressure (ICP), and poor clinical outcomes. Venous acid-base
analysis may therefore be a widely available and inexpensive marker of pulmonary
interstitial edema and elevated ICP in preeclampsia, with potentially important impact on
anesthesia care. Therefore, one aim is to evaluate the association between elevated base
excess to changes in albumin concentration (BE(Alb)) with pulmonary interstitial edema and
increased ICP (both evaluated with non-invasive ultrasound) in patients with late onset
severe preeclampsia. Investigators will further evaluate for an association with urgent
delivery (fetal or maternal indication).
Long-term goal will be to use findings to guide clinical decision-making by anaesthetists to
identify individual patients with acute organ system failures, helping better plan
anaesthetic management during Cesarean delivery. Also, the findings from a larger future
study could predict maternal and fetal complications, and show differences between early-
and late onset disease. This should be of significant future benefit in the South African
context, where preeclampsia is a leading cause of maternal morbidity and mortality.
II. Aims
Aim 1: To explore the association between ultrasound findings and/or venous acid-base
abnormalities, with urgent delivery.
It is hypothesised that patients with acid-base changes secondary to albumin, interstitial
edema and/or elevated ICP will experience a greater proportion of urgent deliveries,
compared to patients without these abnormalities.
Aim 2: To determine the association between pulmonary interstitial edema and increased ICP
with changes in BE(Alb).
Primary Hypothesis: Based on prior studies showing the association of low albumin with
increased extravascular lung water and worse cerebral edema it is hypothesised that the mean
BE(Alb) will be higher in patients with pulmonary interstitial edema and increased ICP
(assessed with POC ultrasound), compared to patients without interstitial edema and normal
ICP. Point-of-care ultrasound is a validated method of identifying both pulmonary
interstitial edema and elevated ICP.
Sample size calculations:
Aim 1: Among patients with late onset disease, prior data suggests that 30% of patients will
have a BE(Alb) > 4 meq/L, with a rate of fetal distress >70% in this population, as compared
to a fetal distress rate of 25% in women with a BE(Alb) < 4 meq/L. Based on the observation
that 70% of women in late onset disease will have a BE(Alb) < 4 meq/L at diagnosis, and
considering an alpha level of 0.05 and power of 0.8, 70 patients will be needed to reject
null hypothesis of predicting delivery status with BE(alb) > 4mEq/L.
Aim 2: In addition, available data suggests that the incidence of elevated intracranial
pressure and interstitial pulmonary edema diagnosed by ultrasound in severe preeclampsia is
approximately 25%, and an elevated BE (Alb) is found in approximately 30% of patients with
severe preeclampsia. Prior data in critically ill patients indicates a mean albumin of 2.8
g/dL (SD 0.7) in patients with normal lung water, compared a mean albumin of 2.2 g/dL (SD
0.7) in patients with increased lung water. When converted to the BE (Alb) scale (assuming a
mean pH of 7.4) and with the biologically plausible assumption of a similar relationship
with ICP, in order to show a statistically meaningful difference in the mean BE (Alb) level
among patients with severe preeclampsia with and without interstitial edema and with and
without elevated ICP, we will need to recruit a total of 80 patients, with an alpha level of
0.05 and a power of 0.9. Furthermore, on the BE (Alb) scale, the mean BE (Alb) of the low
albumin group (mean albumin of 2.2 g/dL) is approximately equal to a BE (Alb) of 4 meq/L and
may represent an important clinical endpoint. Thus, assuming a normal distribution, 50% of
this group is expected to have a BE (Alb) > 4 meq/L. The increased albumin group (mean
albumin of 2.8 g/dL) lies approximately 1 standard deviation from the decreased albumin
group, and assuming a normal distribution, we would expect 18% of this group to exceed the
BE (Alb) > 4 meq/L cut point. Using these two proportions, a chi-squared test with a sample
ratio of 3:1, power of 0.8, and alpha level of 0.05 will require a total sample size of 84
patients (21 with the ultrasound findings and 63 without findings).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03299777 -
Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan
|
N/A | |
Completed |
NCT03650790 -
C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies
|
N/A | |
Recruiting |
NCT03605511 -
TTP and aHUS in Complicated Pregnancies
|
||
Not yet recruiting |
NCT03302260 -
Identifying Methods for Postpartum Reduction of Vascular Events: Pilot Randomized Controlled Trial
|
N/A | |
Completed |
NCT02911701 -
Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
|
Phase 4 | |
Completed |
NCT01911494 -
Community Level Interventions for Pre-eclampsia
|
N/A | |
Terminated |
NCT02025426 -
Phenylephrine Versus Ephedrine in Pre-eclampsia
|
Phase 4 | |
Completed |
NCT01352234 -
Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
|
Phase 4 | |
Active, not recruiting |
NCT02031393 -
Establishing First Trimester Markers for the Identification of High Risk Twin
|
N/A | |
Terminated |
NCT00141310 -
Sildenafil Citrate for the Treatment of Established Pre-Eclampsia
|
Phase 2 | |
Completed |
NCT00157521 -
L-Arginine in Pre-Eclampsia
|
Phase 3 | |
Completed |
NCT04795154 -
Prenatal Yoga as Complementary Therapy of Preeclampsia
|
N/A | |
Completed |
NCT00004399 -
Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia
|
N/A | |
Completed |
NCT00005207 -
Renin and Prorenin in Pregnancy
|
N/A | |
Recruiting |
NCT04551807 -
Natural Versus Programmed Frozen Embryo Transfer (NatPro)
|
Phase 3 | |
Terminated |
NCT04092829 -
Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer
|
N/A | |
Recruiting |
NCT06067906 -
Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients
|
N/A | |
Recruiting |
NCT06317467 -
Role of Anti-C1q Autoantibodies in Pregnancy
|
||
Completed |
NCT02218931 -
ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes
|
N/A | |
Active, not recruiting |
NCT04484766 -
Preeclampsia Associated Vascular Aging
|